{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:54:58Z","timestamp":1778144098534,"version":"3.51.4"},"reference-count":39,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: Sleeping sickness and malaria alike are insect-borne protozoan diseases that share overlapping endemic areas in sub-Saharan Africa. The causative agent for malaria has developed resistance against all currently deployed anti-malarial agents. In the case of sleeping sickness, the currently deployed therapeutic options are limited in efficacy and activity spectra, and there are very few drug candidates in the development pipeline. Thus, there is a need to search for new drug molecules with a novel mode of actions. Materials and Methods: In the current study, an in vitro screening of a library of tetralone derivatives and related benzocycloalkanones was effected against T. b. brucei and P. falciparum. Results: Several hits with low micromolar activity (0.4\u20138 \u00b5M) against T. b. brucei were identified. Conclusions: The identified hits have a low molecular weight (&lt;280 Da), a low total polar surface area (&lt;50 \u212b\u00b2), and a defined structure activity relationship, which all make them potential starting points for further hit optimization studies.<\/jats:p>","DOI":"10.3390\/medicina55050206","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T11:20:46Z","timestamp":1558696846000},"page":"206","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Anti-Trypanosomal and Antimalarial Properties of Tetralone Derivatives and Structurally Related Benzocycloalkanones"],"prefix":"10.3390","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6282-043X","authenticated-orcid":false,"given":"Richard M.","family":"Beteck","sequence":"first","affiliation":[{"name":"Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2440-4993","authenticated-orcid":false,"given":"Lesetja J.","family":"Legoabe","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Centre for Chemico- and Biomedicinal Research, Rhodes University, Grahamstown 6140, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-5738","authenticated-orcid":false,"given":"Setshaba D.","family":"Khanye","sequence":"additional","affiliation":[{"name":"Centre for Chemico- and Biomedicinal Research, Rhodes University, Grahamstown 6140, South Africa"},{"name":"Division of Pharmaceutical Chemistry, Faculty of Pharmacy, Rhodes University, Grahamstown 6140, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2734-0999","authenticated-orcid":false,"given":"Dustin","family":"Laming","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Microbiology, Rhodes University, Grahamstown 6140, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-1955","authenticated-orcid":false,"given":"Heinrich C.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Centre for Chemico- and Biomedicinal Research, Rhodes University, Grahamstown 6140, South Africa"},{"name":"Department of Biochemistry and Microbiology, Rhodes University, Grahamstown 6140, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1046\/j.1365-3156.2001.00775.x","article-title":"The phenomenon of treatment failures in human African trypanosomiasis","volume":"6","author":"Brun","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(03)14694-6","article-title":"The trypanosomiases","volume":"362","author":"Barrett","year":"2003","journal-title":"Lancet"},{"key":"ref_3","unstructured":"Beteck, R.M., Legoabe, L.J., Isaacs, M., and Hoppe, H.C. (2018). In vitro Anti-trypanosomal activities of indanone-based chalcones. Drug Res., 68."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","article-title":"Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness","volume":"55","author":"Kaiser","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"MacLean, L., Reiber, H., Kennedy, P., and Sternberg, J. (2012). Stage progression and neurological symptoms in trypanosoma brucei rhodesience sleeping sickness: Role of the CNS inflammatory response. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001857"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1172\/JCI200421052","article-title":"Human African trypanosomiasis of the CNS: Current issues and challenges","volume":"113","author":"Kennedy","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/bmj.325.7357.203","article-title":"Human African trypanosomiasis","volume":"325","author":"Stich","year":"2002","journal-title":"BMJ"},{"key":"ref_8","first-page":"16","article-title":"Estimates of the duration of the early and late stage of gambiense sleeping sickness","volume":"8","author":"Checchi","year":"2008","journal-title":"Infect. Dis."},{"key":"ref_9","unstructured":"(2018, December 28). Global Health Observatory Data. Available online: http:\/\/www.who.int\/gho\/neglected_diseases\/human_african_trypanosomiasis\/en\/."},{"key":"ref_10","unstructured":"Kuepfer, I., Hhary, E., Allan, M., Edielu, A., Burri, C., and Blum, J. (2011). Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS. Negl. Trop. Dis., 5."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Simarro, P., Cecchi, G., Franco, J., Paone, M., Diarra, A., Ruiz-Postigo, J., Fe\u2019vre, E., Mattioli, R., and Jannin, G. (2012). Estimating and mapping the population at risk of sleeping sickness. PLoS. Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001859"},{"key":"ref_12","first-page":"257","article-title":"Epidemiology of human African trypanosomiasis","volume":"6","author":"Franco","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1179\/2047773213Y.0000000105","article-title":"A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis","volume":"107","author":"Babokhov","year":"2013","journal-title":"Pathog. Glob. Health"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Song, J., Baker, N., Rothert, M., Henke, B., Jeacock, L., Horn, D., and Beitz, E. (2016). Pentamidine is not a permeant but a nanomolar inhibitor of the Trypanosoma brucei aquaglyceroporin-2. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005436"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: M\u00e9decins San Fronti\u00e8res experience in the Democratic Republic of Congo","volume":"56","author":"Alirol","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-3305-3-15","article-title":"The development of drugs for treatment of sleeping sickness: A historical review","volume":"3","author":"Steverding","year":"2010","journal-title":"Parasit. Vectors"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.17159\/0379-4350\/2018\/v71a25","article-title":"Synthesis, in vitro cytotoxicity and trypanocidal evaluation of novel 1,3,6-substituted non-fluoroquinolones","volume":"71","author":"Beteck","year":"2018","journal-title":"S. Afr. J. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1039\/C7MD00280G","article-title":"Novel lead compounds in pre-clinical development against African sleeping sickness","volume":"8","author":"Berninger","year":"2017","journal-title":"Med. Chem. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/BF03402046","article-title":"Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei","volume":"6","author":"Troeberg","year":"2000","journal-title":"Mol. Med."},{"key":"ref_20","first-page":"379","article-title":"The impact of nagana","volume":"61","author":"Connor","year":"1994","journal-title":"Onderstepoort. J. Vet. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1017\/S0031182016001268","article-title":"The animal trypanosomiases and their chemotherapy: A review","volume":"143","author":"Giordani","year":"2016","journal-title":"Parasitology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1039\/C8MD00319J","article-title":"Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery","volume":"9","author":"Veale","year":"2018","journal-title":"Med. Chem. Commun."},{"key":"ref_23","unstructured":"WHO (2018). World Malaria Report 2018, World Health Organization."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1475-2875-10-188","article-title":"Is the current decline in malaria burden in sub-Saharan Africa due to a decrease in vector population?","volume":"10","author":"Meyrowitsch","year":"2011","journal-title":"Mal. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1126\/science.358.6360.155","article-title":"Drug-resistant malaria advances in Mekong","volume":"358","author":"Roberts","year":"2017","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e201245","DOI":"10.4084\/mjhid.2012.045","article-title":"Prophylaxis of Malaria","volume":"4","author":"Schwartz","year":"2012","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1472-8206.2009.00709.x","article-title":"Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development","volume":"23","author":"Karbwang","year":"2009","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_29","first-page":"1598","article-title":"Plasmodium falciparum malaria and antimalarial interventions in sub-Saharan Africa: Challenges and opportunities","volume":"4","author":"Enato","year":"2005","journal-title":"Afr. J. Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/17460441.2016.1154037","article-title":"Resisting resistance: Is there a solution for malaria?","volume":"11","author":"Verlinden","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/acs.jmedchem.5b00515","article-title":"Protozoan parasite growth inhibitors discovered by cross-screening yield potent scaffolds for lead discovery","volume":"58","author":"Devine","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Spangenberg, T., Burrows, J.N., Kowalczyk, P., McDonald, S., Wells, T.N., and Willis, P. (2013). The open access malaria box: A drug discovery catalyst for neglected diseases. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062906"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Van Voorhis, W.C., Adams, J.H., Adelfio, R., Ahyong, V., Akabas, M., Alano, P., Alday, A., Resto, Y., Alsibaee, A., and Alzualde, A. (2016). Open source drug discovery with the malaria box compound collection for neglected diseases and beyond. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005763"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/cmdc.201800404","article-title":"Brain-penetrant, triazolopyrimidine and phenylpyrimidine microtubule-stabilizers as potential leads to treat Human African Trypanosomiasis","volume":"13","author":"Monti","year":"2018","journal-title":"ChemMedChem"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1055\/a-0620-8309","article-title":"Synthesis and in vitro evaluation of 2-heteroarylidene-1-tetralone derivatives as monoamine oxidase inhibitors","volume":"68","author":"Amakali","year":"2018","journal-title":"Drug Res. (Stuttg.)"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/1871524918666180501121638","article-title":"Synthesis and valuation of 2-benzylidene-1-tetralone derivatives for monoamine oxidase inhibitory activity","volume":"18","author":"Amakali","year":"2018","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gumbo, M., Beteck, R.M., Mandizvo, T., Seldon, R., Warner, D.F., Hoppe, H.C., Isaacs, M., Laming, D., Tam, C.C., and Cheng, L.W. (2018). Cinnamoyl-Oxaborole Amides: Synthesis and Their in Vitro Biological Activity. Molecules, 23.","DOI":"10.3390\/molecules23082038"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.17159\/0379-4350\/2018\/v71a23","article-title":"Synthesis, antiplasmodial and antitrypanosomal evaluation of a series of novel 2-oxoquinoline-based thiosemicarbazone derivatives","volume":"71","author":"Darrell","year":"2018","journal-title":"S. Afr. J. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4269\/ajtmh.1993.48.739","article-title":"Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity","volume":"48","author":"Makler","year":"1993","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/5\/206\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:54:49Z","timestamp":1760187289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/5\/206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["medicina55050206"],"URL":"https:\/\/doi.org\/10.3390\/medicina55050206","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]}}}